-
1
-
-
0141857724
-
Developmental pharmacology - drug disposition, action, and therapy in infants and children
-
Kearns G.L., et al. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349 (2003) 1157-1167
-
(2003)
N. Engl. J. Med.
, vol.349
, pp. 1157-1167
-
-
Kearns, G.L.1
-
2
-
-
0037350150
-
Research in children
-
Burns J.P. Research in children. Crit. Care Med. 31 3 Suppl. (2003) S131-136
-
(2003)
Crit. Care Med.
, vol.31
, Issue.3 SUPPL
-
-
Burns, J.P.1
-
3
-
-
4444351808
-
Clinical trials in children
-
Caldwell P.H., et al. Clinical trials in children. Lancet 364 (2004) 803-811
-
(2004)
Lancet
, vol.364
, pp. 803-811
-
-
Caldwell, P.H.1
-
4
-
-
61649109321
-
Challenges for drug studies in children: CYP3A phenotyping as example
-
[Epub ahead of print]
-
de Wildt S.N., et al. Challenges for drug studies in children: CYP3A phenotyping as example. Drug Discov. Today (2008) [Epub ahead of print]
-
(2008)
Drug Discov. Today
-
-
de Wildt, S.N.1
-
5
-
-
0036020410
-
Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands
-
t Jong G.W., et al. Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur. J. Clin. Pharmacol. 58 (2002) 293-297
-
(2002)
Eur. J. Clin. Pharmacol.
, vol.58
, pp. 293-297
-
-
t Jong, G.W.1
-
6
-
-
20244368931
-
Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children
-
Conroy S., et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 320 (2000) 79-82
-
(2000)
BMJ
, vol.320
, pp. 79-82
-
-
Conroy, S.1
-
7
-
-
0034642054
-
Unapproved and off-label use of drugs in a children's hospital
-
t Jong G.W., et al. Unapproved and off-label use of drugs in a children's hospital. N. Engl. J. Med. 343 (2000) 1125
-
(2000)
N. Engl. J. Med.
, vol.343
, pp. 1125
-
-
t Jong, G.W.1
-
8
-
-
80051823470
-
Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol
-
Sutherland J.M. Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. AMA J. Dis. Child. 97 (1959) 761-767
-
(1959)
AMA J. Dis. Child.
, vol.97
, pp. 761-767
-
-
Sutherland, J.M.1
-
9
-
-
0021725723
-
E-ferol: what happened and what now?
-
Phelps D.L. E-ferol: what happened and what now?. Pediatrics 74 (1984) 1114-1116
-
(1984)
Pediatrics
, vol.74
, pp. 1114-1116
-
-
Phelps, D.L.1
-
10
-
-
0000022275
-
A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens
-
Andersen D.H., et al. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 18 (1956) 614-625
-
(1956)
Pediatrics
, vol.18
, pp. 614-625
-
-
Andersen, D.H.1
-
11
-
-
0030890279
-
Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The 'wooden shoe' paradigm
-
Breimer D.D., and Danhof M. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The 'wooden shoe' paradigm. Clin. Pharmacokinet. 32 (1997) 259-267
-
(1997)
Clin. Pharmacokinet.
, vol.32
, pp. 259-267
-
-
Breimer, D.D.1
Danhof, M.2
-
12
-
-
0033382294
-
Cytochrome P450 3A: ontogeny and drug disposition
-
de Wildt S.N., et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet. 37 (1999) 485-505
-
(1999)
Clin. Pharmacokinet.
, vol.37
, pp. 485-505
-
-
de Wildt, S.N.1
-
13
-
-
0028869017
-
Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin
-
van den Anker J.N., et al. Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. Br. J. Clin. Pharmacol. 40 (1995) 439-443
-
(1995)
Br. J. Clin. Pharmacol.
, vol.40
, pp. 439-443
-
-
van den Anker, J.N.1
-
14
-
-
0035699615
-
Ontogeny of drug-metabolizing enzymes and its influence on the pathogenesis of adverse drug reactions in children
-
Leeder J.S. Ontogeny of drug-metabolizing enzymes and its influence on the pathogenesis of adverse drug reactions in children. Curr. Ther. Res. 62 (2001) 900-912
-
(2001)
Curr. Ther. Res.
, vol.62
, pp. 900-912
-
-
Leeder, J.S.1
-
15
-
-
42049113033
-
Pediatric antihypertensive trial failures: analysis of end points and dose range
-
Benjamin Jr. D.K., et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension 51 (2008) 834-840
-
(2008)
Hypertension
, vol.51
, pp. 834-840
-
-
Benjamin Jr., D.K.1
-
16
-
-
0032494103
-
Impact of pharmacodynamic variability on drug delivery
-
Levy G. Impact of pharmacodynamic variability on drug delivery. Adv. Drug Deliv. Rev. 33 (1998) 201-206
-
(1998)
Adv. Drug Deliv. Rev.
, vol.33
, pp. 201-206
-
-
Levy, G.1
-
17
-
-
34548203082
-
Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations
-
Krekels E.H., et al. Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations. Expert Opin. Pharmacother. 8 (2007) 1787-1799
-
(2007)
Expert Opin. Pharmacother.
, vol.8
, pp. 1787-1799
-
-
Krekels, E.H.1
-
18
-
-
41949118720
-
Covariates of tramadol disposition in the first months of life
-
Allegaert K., et al. Covariates of tramadol disposition in the first months of life. Br. J. Anaesth. 100 (2008) 525-532
-
(2008)
Br. J. Anaesth.
, vol.100
, pp. 525-532
-
-
Allegaert, K.1
-
19
-
-
47949109211
-
Developmental changes in human liver CYP2D6 expression
-
Stevens J.C., et al. Developmental changes in human liver CYP2D6 expression. Drug Metab. Dispos. 36 (2008) 1587-1593
-
(2008)
Drug Metab. Dispos.
, vol.36
, pp. 1587-1593
-
-
Stevens, J.C.1
-
20
-
-
49949152544
-
Using ontogeny information to build predictive models for drug elimination
-
Alcorn J., and McNamara P.J. Using ontogeny information to build predictive models for drug elimination. Drug Discov. Today 13 (2008) 507-512
-
(2008)
Drug Discov. Today
, vol.13
, pp. 507-512
-
-
Alcorn, J.1
McNamara, P.J.2
-
21
-
-
46149121257
-
Recent development in application of high performance liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressants
-
Yang Z., and Wang S. Recent development in application of high performance liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressants. J. Immunol. Methods 336 (2008) 98-103
-
(2008)
J. Immunol. Methods
, vol.336
, pp. 98-103
-
-
Yang, Z.1
Wang, S.2
-
22
-
-
0035021127
-
Use of saliva in therapeutic drug monitoring of caffeine in preterm infants
-
de Wildt S.N., et al. Use of saliva in therapeutic drug monitoring of caffeine in preterm infants. Ther. Drug Monit. 23 (2001) 250-254
-
(2001)
Ther. Drug Monit.
, vol.23
, pp. 250-254
-
-
de Wildt, S.N.1
-
23
-
-
0032832768
-
The use of the dried blood spot sample in epidemiological studies
-
Parker S.P., and Cubitt W.D. The use of the dried blood spot sample in epidemiological studies. J. Clin. Pathol. 52 (1999) 633-639
-
(1999)
J. Clin. Pathol.
, vol.52
, pp. 633-639
-
-
Parker, S.P.1
Cubitt, W.D.2
-
24
-
-
0031594230
-
Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test
-
Parker A.C., et al. Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br. J. Clin. Pharmacol. 45 (1998) 176-178
-
(1998)
Br. J. Clin. Pharmacol.
, vol.45
, pp. 176-178
-
-
Parker, A.C.1
-
25
-
-
0003747347
-
-
Division of Clinical Pharmacology, University of California at San Francisco
-
Boeckmann A.J., et al. NONMEM User's Guide (1998), Division of Clinical Pharmacology, University of California at San Francisco
-
(1998)
NONMEM User's Guide
-
-
Boeckmann, A.J.1
-
26
-
-
20644445856
-
Modelling approaches to dose estimation in children
-
Johnson T.N. Modelling approaches to dose estimation in children. Br. J. Clin. Pharmacol. 59 (2005) 663-669
-
(2005)
Br. J. Clin. Pharmacol.
, vol.59
, pp. 663-669
-
-
Johnson, T.N.1
-
27
-
-
34247173459
-
Population pharmacokinetic model for gatifloxacin in pediatric patients
-
Rubino C.M., et al. Population pharmacokinetic model for gatifloxacin in pediatric patients. Antimicrob. Agents Chemother. 51 (2007) 1246-1252
-
(2007)
Antimicrob. Agents Chemother.
, vol.51
, pp. 1246-1252
-
-
Rubino, C.M.1
-
28
-
-
14744276100
-
Pharmacokinetics of gatifloxacin in infants and children
-
Capparelli E.V., et al. Pharmacokinetics of gatifloxacin in infants and children. Antimicrob. Agents Chemother. 49 (2005) 1106-1112
-
(2005)
Antimicrob. Agents Chemother.
, vol.49
, pp. 1106-1112
-
-
Capparelli, E.V.1
-
29
-
-
33751335379
-
Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery
-
Peeters M.Y., et al. Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Anesthesiology 105 (2006) 1135-1146
-
(2006)
Anesthesiology
, vol.105
, pp. 1135-1146
-
-
Peeters, M.Y.1
-
30
-
-
33645511875
-
Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery
-
Peeters M.Y., et al. Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology 104 (2006) 466-474
-
(2006)
Anesthesiology
, vol.104
, pp. 466-474
-
-
Peeters, M.Y.1
-
31
-
-
0029550482
-
Three new residual error models for population PK/PD analyses
-
Karlsson M.O., et al. Three new residual error models for population PK/PD analyses. J. Pharmacokinet. Biopharm. 23 (1995) 651-672
-
(1995)
J. Pharmacokinet. Biopharm.
, vol.23
, pp. 651-672
-
-
Karlsson, M.O.1
-
32
-
-
0027049043
-
Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects
-
Mandema J.W., et al. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokinet. Biopharm. 20 (1992) 511-528
-
(1992)
J. Pharmacokinet. Biopharm.
, vol.20
, pp. 511-528
-
-
Mandema, J.W.1
-
33
-
-
40549143738
-
Facilitation of drug evaluation in children by population methods and modelling
-
Tod M., et al. Facilitation of drug evaluation in children by population methods and modelling. Clin. Pharmacokinet. 47 (2008) 231-243
-
(2008)
Clin. Pharmacokinet.
, vol.47
, pp. 231-243
-
-
Tod, M.1
-
34
-
-
33750581706
-
Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide
-
Brendel K., et al. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm. Res. 23 (2006) 2036-2049
-
(2006)
Pharm. Res.
, vol.23
, pp. 2036-2049
-
-
Brendel, K.1
-
35
-
-
0033574245
-
Assessing the generalizability of prognostic information
-
Justice A.C., et al. Assessing the generalizability of prognostic information. Ann. Intern. Med. 130 (1999) 515-524
-
(1999)
Ann. Intern. Med.
, vol.130
, pp. 515-524
-
-
Justice, A.C.1
-
36
-
-
0034608969
-
Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group
-
McGinn T.G., et al. Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. JAMA 284 (2000) 79-84
-
(2000)
JAMA
, vol.284
, pp. 79-84
-
-
McGinn, T.G.1
-
37
-
-
0002322365
-
Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM
-
Jonsson E.N., and Karlsson M.O. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58 (1999) 51-64
-
(1999)
Comput. Methods Programs Biomed.
, vol.58
, pp. 51-64
-
-
Jonsson, E.N.1
Karlsson, M.O.2
-
38
-
-
33847028671
-
Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis
-
Danhof M., et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 357-400
-
(2007)
Annu. Rev. Pharmacol. Toxicol.
, vol.47
, pp. 357-400
-
-
Danhof, M.1
-
39
-
-
0020324807
-
Comparative pharmacokinetics of ceftazidime and moxalactam
-
Tjandramaga T.B., et al. Comparative pharmacokinetics of ceftazidime and moxalactam. Antimicrob. Agents Chemother. 22 (1982) 237-241
-
(1982)
Antimicrob. Agents Chemother.
, vol.22
, pp. 237-241
-
-
Tjandramaga, T.B.1
|